Formed: 2002

Scientific sources: Patents and investigation by Dr. J.L. Mato (CSIC)

• Activity 1: Development of diagnostic and prognostic kits for common, advanced stage, diseases of the liver
  

• Product:  Blood and/or urine kit

• Value proposition: First non-invasive prognostic kit that avoids biopsy. At present there is no method for early diagnosis.

• Intellectual Property: Various patents related to the diagnosis of hepatic diseases

• Development stage: Development and validation
  

• Market size: More than 100 million people suffer from liver diseases, in many cases underdiagnosed

• Activity 2: Commercialisation of testing services for metabolite indicators of illnesses, toxicity of products, etc. 

• Product: Services of Research and Development to third parties, services of a diagnostic clinic

• Value Proposition:  Unique experience and skills in the design, analysis, and interpretation of metabolic studies
  

• Development stage: At present Owl Genomics is commercialising its services

• Market size: It was estimated to be $700 million in 2007 and is forecast to multiply to more than  $2 billion in 2012